PHAT
Phathom Pharmaceuticals Inc

2,372
Mkt Cap
$1.05B
Volume
475,696.00
52W High
$16.08
52W Low
$2.21
PE Ratio
-3.88
PHAT Fundamentals
Price
$14.36
Prev Close
$14.79
Open
$14.92
50D MA
$12.79
Beta
1.23
Avg. Volume
1.26M
EPS (Annual)
-$5.29
P/B
-2.49
Rev/Employee
$129,395.79
Loading...
Loading...
News
all
press releases
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Simplify Asset Management Inc. Sells 160,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT
Simplify Asset Management Inc. decreased its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 23.5% in the 2nd quarter, according to its most recent 13F filing with...
MarketBeat·8d ago
News Placeholder
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +50.00% and +0.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22d ago
News Placeholder
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
Phathom Pharmaceuticals (PHAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·2mo ago
News Placeholder
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·3mo ago
News Placeholder
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
MannKind (MNKD) Reports Break-Even Earnings for Q2
MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
Zacks·5mo ago

Latest PHAT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.